Socialization of Adult Men With Congenital Hemophilia A or B

Key facts

Sponsor

Dana-Farber Cancer Institute

Principal Investigator

Aric Parnes, MD

Brigham and Women's Hospital

Enrollment

27 enrolled

Eligibility

21 years · All sexes

Timeline

2011 – 2013

Study locations (1)

• Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Collaborators

Brigham and Women's Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hemophilia A

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE4NCT05936580
  Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
  Octapharma
• ACTIVE NOT RECRUITINGNCT07161687
  A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.
  Pfizer
• RECRUITINGPHASE4NCT06864975
  Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)
  Runhui WU
• RECRUITINGPHASE1NCT06579144
  Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A
  Swedish Orphan Biovitrum
• RECRUITINGPHASE3NCT06738485
  Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
  CSL Behring
• RECRUITINGNCT06684314
  A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan
  Sanofi
• RECRUITINGNCT07414511
  Hemophilia A Research Program
  University of Washington
• RECRUITINGEARLY PHASE1NCT06345833
  Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study
  University of Minnesota

See all trials for Hemophilia A →